Search details
1.
In vivo maintenance of human regulatory T cells during CD25 blockade.
J Immunol
; 194(1): 84-92, 2015 Jan 01.
Article
in English
| MEDLINE | ID: mdl-25416807
2.
Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis.
Mult Scler
; 17(12): 1441-8, 2011 Dec.
Article
in English
| MEDLINE | ID: mdl-21807759
3.
First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma.
Clin Cancer Res
; 26(10): 2308-2317, 2020 05 15.
Article
in English
| MEDLINE | ID: mdl-31969330
4.
Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials.
Clin Pharmacokinet
; 55(1): 121-30, 2016 Jan.
Article
in English
| MEDLINE | ID: mdl-26242380
5.
The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax®.
MAbs
; 8(7): 1417-1424, 2016 10.
Article
in English
| MEDLINE | ID: mdl-27367933
6.
Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis.
Expert Rev Clin Pharmacol
; 7(1): 9-19, 2014 Jan.
Article
in English
| MEDLINE | ID: mdl-24308792
Results
1 -
6
de 6
1
Next >
>>